Dyne Therapeutics, Inc.

DYN Nasdaq SEC CIK 1818794
Follow Dyne Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$193.6M −79.1% vs same quarter last year
EPS, diluted −$1.06 −39.5% vs same quarter last year
Operating cash flow −$177.5M −95.5% vs same quarter last year
Operating income −$197.1M −73% vs same quarter last year
Net income by quarter
$227.9M
−$115.4M
−$110.9M
−$108M
$334.3M
−$120.9M
−$178.6M
−$193.6M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
−$150M−$100M−$50M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$446.2
FY24−$317.4
FY23−$235.9
FY22−$168.1
FY21−$149.3M
FY20−$59.4M
FY19−$14.9M
FY18-
Free cash flowOperating cash flow minus capital expenditure
−$600M−$400M−$200M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$405.1M
FY24−$294.7M
FY23−$188.9M
FY22−$156.7M
FY21−$123.2M
FY20−$47.7M
FY19−$13.5M
FY18-